Ethyl acetate extract - Hanmi Pharmaceutical

Drug Profile

Ethyl acetate extract - Hanmi Pharmaceutical

Alternative Names: Acetates; ALS-L1023; McEye; Melissa leaf ethyl acetate dried extract

Latest Information Update: 17 Oct 2016

Price : $50

At a glance

  • Originator AngioLab Inc
  • Developer AngioLab Inc; Hanmi Pharmaceutical
  • Class Acetates; Herbal medicines; Obesity therapies
  • Mechanism of Action Angiogenesis inhibitors; Matrix metalloproteinase inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diabetic macular oedema; Diabetic retinopathy; Retinopathy of prematurity

Highest Development Phases

  • Preclinical Eye disorders; Obesity

Most Recent Events

  • 17 Oct 2016 No development reported - Phase-III for Obesity in South Korea (PO)
  • 01 Jan 2015 Hanmi Pharmaceutical terminates a phase III trial in Obesity in South Korea (NCT01872182)
  • 30 Nov 2012 Phase-III clinical trials in Obesity in South Korea (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top